1 research outputs found
Dental Treatment of the Patient with Porphyria
Porfirije su skupina nasljednih bolesti uzrokovanih defektnim enzimima na biosintetskom putu hema. Ovisno o defektu pojedinog enzima razlikujemo i razne vrste porfirija. Posljedica defekta enzima jest stvaranje abnormalnih koliÄina prekursora hema (porfirina) koji se nakupljaju u tkivima i izluÄuju mokraÄom i stolicom. KliniÄki znaci gotovo potpuno proizlaze iz uÄinka tih spojeva na živÄani sustav i kožu. Mnogi lijekovi, kao lokalni anestetici (lidokain), antibiotici (klindamicin, eritromicin, metronidazol) i dr. spadaju u precipitirajuÄe Äimbenike i mogu uzrokovati akutne napade. Pacijentima s porfirijom sa sigurnoÅ”Äu se mogu dati bupivakain, amoksicilin, klavulanska kiselina, acetilsalicilna kiselina, paracetamol (1,2).
Zato je stomatologu važno imati odreÄene smjernice u sluÄaju lijeÄenja pacijenta s nekim akutnim oblikom porfirije.Porphyria is a group of inherited diseases caused by defective enzymes on the biosynthetic pathway of heme. Depending on the specific enzyme defect different forms of porphyria can be differentiated. The consequence of the enzyme defect is the formation of abnormal amounts of porphyrins or precursors which accumulate in the tissues and are excreted in the urine and faeces. Almost all the clinical signs occur because of the effect of these compounds/products on the nervous system and skin. Numerous drugs, such as local anaesthetics (lidocaine), antibiotics (clindamycin, erythromycin, metronidazole) and others, can be precipitating factors and cause acute attacks. Patients with porphyria can safely be given bupivacaine, amoxycillin, clavulanic acid, acethylsalicilic acid and paracetamol (1, 2).
Thus it is important for the dentist to have certain guidelines with regard to the treatment of patients with acute form of porphyria